Drug Profile
Research programme: GABA transport inhibitors - Novo Nordisk/BTG
Alternative Names: GABA transport inhibitors research programme - Novo Nordisk/BTGLatest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Developer BTG
- Class
- Mechanism of Action GABA uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Epilepsy; Pain
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 24 Feb 1999 New profile
- 24 Feb 1999 Preclinical development for Epilepsy in United Kingdom (Unknown route)